Skip to main content

Main navigation

  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Main navigation

  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Psychopharmacology

Medication in hand
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?

Welcome to Schizophrenia Knowledge Base

This website is intended for healthcare professionals in the United States.

Yes, I am a US healthcare professional
No, I am not a US healthcare professional
Medication in hand
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?
Medication
CME: Optimizing the Utility of Muscarinic Acetylcholine Receptor Activators in Clinical Practice
Medication
CME: Interpreting the Latest Clinical Data and Treatment Implications for Approved and Emerging Muscarinic Acetylcholine Receptor Activators in Schizophrenia
Medication
CME: Understanding Muscarinic Acetylcholine Receptor Activation as a Therapeutic Target in Schizophrenia
Medication
CME: Harnessing the Evolving Understanding of Schizophrenia to Address Treatment Challenges and Unmet Needs
Symptoms
Understanding the Cholinergic System
Elder Pt Confused by Medication
Assessing Anticholinergic Burden
Medication
Anticholinergic Misuse: Can These Medications Be Addictive?
Brain image
Can Anticholinergic Medications Make Movement Disorders Worse?
Brain image
What’s the Role of Amantadine in Anticholinergic Deprescription?

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page Next ›
  • Last page Last »
© 2025 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use Cookie Policy